Papers - SHIMA Hiroaki

乳房部分切除後の温存乳房内再発時の手術術式選択に関する患者意向について

瀬戸 友希子, 石飛 真人, 枝園 忠彦, 大城 智弥, 井上 寛章, 島 宏彰, 久芳 さやか, 渡邉 法之, 岩谷 胤生, 中山 貴寛

日本乳癌学会総会プログラム抄録集 ( (一社)日本乳癌学会 )  32回   261 - 261  2024.07

ASO Visual Abstract: Patient Preference for Surgical Methods for Ipsilateral Breast Tumor Recurrence.

Yukiko Seto, Makoto Ishitobi, Tadahiko Shien, Chiya Oshiro, Hiroaki Inoue, Hiroaki Shima, Sayaka Kuba, Noriyuki Watanabe, Tsuguo Iwatani, Takahiro Nakayama

Annals of surgical oncology    2024.05  [International journal]

DOI PubMed

ロボット手術用drop-in probeを用いた乳房部分切除における切除範囲最適化の模索

島 宏彰, 九冨 五郎, 和田 朝香, 里見 蕗乃, 野田 愛, 竹政 伊知朗

北海道外科雑誌 ( 北海道外科学会 )  68 ( 2 ) 177 - 177  2023.12

パルボシクリブにより左乳癌胸壁再発の局所制御を5年以上維持できた1例

館山 紋奈, 島 宏彰, 和田 朝香, 里見 蕗乃, 野田 愛, 九冨 五郎, 竹政 伊知朗

北海道外科雑誌 ( 北海道外科学会 )  68 ( 2 ) 172 - 172  2023.12

オンラインPRO情報システムによるがん手術患者の術創部感染症の危険因子と予後の検証

石貫 智裕, 久冨 五郎, 島 宏彰, 和田 朝香, 青木 武士, 吉田 寛, 渡邉 学, 長田 拓哉, 横尾 英樹, 問山 裕二, 大西 浩文, 林 宏至, 森脇 健介, 大柳 俊夫, 水口 徹

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  61回   P61 - 5  2023.10

癌幹細胞マーカーに対する自己抗体を利用した乳癌患者の予後予測(Prediction of Prognosis in Breast Cancer Patients Using Autoantibodies to Cancer Stem Cell Markers)

及能 大輔, 廣橋 良彦, 和田 朝香, 島 宏彰, 九冨 五郎, 真柄 和史, 高澤 久美, 高澤 啓, 竹政 伊知朗, 小山内 誠

日本癌学会総会記事 ( (一社)日本癌学会 )  82回   2116 - 2116  2023.09

癌幹細胞マーカーに対する自己抗体を利用した乳癌患者の予後予測(Prediction of Prognosis in Breast Cancer Patients Using Autoantibodies to Cancer Stem Cell Markers)

及能 大輔, 廣橋 良彦, 和田 朝香, 島 宏彰, 九冨 五郎, 真柄 和史, 高澤 久美, 高澤 啓, 竹政 伊知朗, 小山内 誠

日本癌学会総会記事 ( (一社)日本癌学会 )  82回   2116 - 2116  2023.09

エリブリンはヒト白血球抗原クラスIのアップレギュレーションによる乳癌の免疫増強因子である(Eribulin is an immune potentiator in breast cancer by up-regulation of human leukocyte antigen class I)

和田 朝香, 九冨 五郎, 廣橋 良彦, 島 宏彰, 及能 大輔, 空閑 陽子, 鳥越 俊彦, 竹政 伊知朗

日本乳癌学会総会プログラム抄録集 ( (一社)日本乳癌学会 )  31回   66 - 66  2023.06

Positional advantages of supine MRI for diagnosis prior to breast‑conserving surgery.

Goro Kutomi, Hiroaki Shima, Daisuke Kyuno, Fukino Satomi, Asaka Wada, Yoko Kuga, Minoru Okazaki, Akira Okazaki, Hideji Masuoka, Toshihiko Mikami, Yuichi Yuyama, Takashi Matsuno, Tosei Ohmura, Hidekazu Kameshima, Toru Mizuguchi, Ichiro Takemasa

Molecular and clinical oncology   18 ( 5 ) 44 - 44  2023.05  [International journal]

　View Summary

The present study aimed to evaluate the rate of positive surgical margins for magnetic resonance imaging (MRI) performed in the supine position prior to breast-conserving surgery (BCS). The rate of positive surgical margins and the clinicopathological factors were examined in consecutive patients with BCS who underwent preoperative MRI performed in the supine position at Sapporo Medical University Hospital (Sapporo, Japan) and related hospitals and clinics between January 2012 and December 2013. Of 1,175 eligible patients, 1,150 were included after excluding 25 patients with either bilateral breast cancer or stage IV disease. Positive margin was defined as no cancer seen on the resected margin. The primary endpoint was the rate of positive surgical margins when preoperative MRI was performed in the supine position and the secondary endpoint was identification of the factors that predict positive margins. Of the 1,150 female patients (median age, 55 years; range, 29-97 years) who underwent BCS for breast cancer following MRI performed in the supine position, 215 (18.8%) had positive margins, which is similar to the rate with MRI in the prone position, and 930 (81.2%) had negative margins. The rate of positive surgical margins in patients of the human epidermal growth factor receptor 2 (HER2) type was significantly higher than that in the non-HER2 type group (6.5 and 2.9%; χ2 P=0.0103). There was no increase in the rate of positive margins in breast cancers with a diameter of >T2. The rate of positive surgical margins following MRI performed in the supine position was 18.8%. Supine MRI appears to be suitable for informing on the extent of resection of breast cancer.

DOI PubMed

Additional effect of anthracycline in preoperative chemotherapy with a sequential anthracycline‑containing regimen preceded by pertuzumab, trastuzumab and docetaxel combination therapy.

Hiroaki Shima, Goro Kutomi, Yoko Kuga, Asaka Wada, Fukino Satomi, Kiminori Sato, Daisuke Kyuno, Noriko Nishikawa, Satoko Uno, Hidekazu Kameshima, Tosei Ohmura, Tadashi Hasegawa, Ichiro Takemasa

Experimental and therapeutic medicine   25 ( 1 ) 68 - 68  2023.01  [International journal]

　View Summary

The proper use of anthracycline-containing regimens in combination with anti-HER2-targeted therapy in a neoadjuvant setting for patients with HER2-positive breast cancer has not been resolved. Regimens preceded by anthracyclines have become the standard of care, and although the order has no significant impact on HER2-negative breast cancer, it is inconclusive as to whether a taxane-first sequence would have a similar effect on HER2-positive breast cancer. The present study aimed to investigate the benefit of a taxane-first sequence and of adriamycin and cyclophosphamide (AC) in patients with non-clinical complete response (non-cCR) to pertuzumab, trastuzumab and docetaxel (PTD). The present single-center prospective observational study was performed to investigate PTD followed by AC, and aimed to clarify the cCR rate after PTD alone and the pathological clinical response (pCR) rate after subsequent AC in patients without cCR after PTD alone. A total 24 patients were analyzed; of these, 14 achieved pCR (pCR rate, 58.3%). While four of 14 patients (28.6%) in the intention-to-treat population achieved pCR, nine of 14 patients (64.3%) achieved pCR with AC but not cCR after PTD. The median tumor reduction rate after four cycles of PTD was 58.9% (range, 20.8-100%) in all 24 patients, whereas the reduction rate after PTD-AC was 76.9% (range, 31.1-100%). Cardiac serious adverse events occurred in three patients (12.5%). In conclusion, a high pCR rate was observed for the taxane-first sequence. Patients were highly responsive to PTD, but some cases achieved additional antitumor effects after AC, which resulted in pCR without cCR after PTD alone. Since cardiotoxicity remains a significant problem, a higher risk-benefit treatment strategy is required to aim for AC omission. Trial registration number: UMIN000046338, name of registry: UMIN-CTR, date of registration: December 10, 2021.

DOI PubMed

Preferences Regarding Breast Surgery Omission Among Patients With Breast Cancer Who Receive Neoadjuvant Chemotherapy.

Kaho Nakamura, Makoto Ishitobi, Chiya Oshiro, Hiroaki Shima, Eriko Takahashi, Takahiro Nakayama, Tadahiko Shien, Kanako Saito, Tsuguo Iwatani, Yukiko Seto, Kaori Terata, Goro Kutomi, Tomoko Ogawa, Hideo Inaji

In vivo (Athens, Greece)   37 ( 2 ) 794 - 800  2023  [International journal]

　View Summary

BACKGROUND/AIM: Currently, several ongoing prospective studies are investigating the safety of breast surgery omission in patients with breast cancer who are exceptional responders to neoadjuvant chemotherapy. However, there is little information about the preferences of these patients regarding omission of breast surgery. PATIENTS AND METHODS: We conducted a questionnaire survey to assess preferences regarding omission of breast surgery among patients with breast cancer who had human epidermal growth factor receptor 2-positive or estrogen receptor-negative tumors and good clinical response after neoadjuvant chemotherapy. Patients' estimation of the risk of ipsilateral breast tumor recurrence (IBTR) after definitive surgery or breast surgery omission was also assessed. RESULTS: Of 93 patients, only 22 (23.7%) said they would omit breast surgery. Under the scenario of omitting breast surgery, the 5-year IBTR rate estimated by patients who said they would omit breast surgery was significantly lower (median, 10%) than the rate estimated by patients who preferred undergoing definitive surgery (median, 30%) (p=0.017). CONCLUSION: The proportion of our surveyed patients who were willing to omit breast surgery was low. Patients who said they preferred to omit breast surgery overestimated the 5-year IBTR risk.

DOI PubMed

YTHDC2 Promotes Malignant Phenotypes of Breast Cancer Cells

Atsushi Tanabe, Takatoshi Nakayama, Jo Kashiyanagi, Hitoshi Yamaga, Yoshihiko Hirohashi, Toshihiko Torigoe, Fukino Satomi, Hiroaki Shima, Hideki Maeda, Goro Kutomi, Ichiro Takemasa, Hiroeki Sahara

Journal of Oncology ( Hindawi Limited )  2022   1 - 11  2022.10

　View Summary

YTH domain-containing 2 (YTHDC2) is known to be an important regulator for RNA metabolism. Here, we show that YTHDC2 is essential for breast cancer tumorigenesis and metastasis. We examined YTHDC2 expression levels by immunohistochemistry in human breast tumor tissues from 99 patients and found a significantly positive correlation between the YTHDC2 expression level and the tumor stage. We established YTHDC2-knocked-down cell lines using four breast cancer cell lines with different subtypes. Knockdown of YTHDC2 attenuated the sphere-forming and the metastatic ability of breast cancer cells. Although stemness and EMT markers, such as SOX2, c-MYC, and NANOG, were downregulated in several YTHDC2-knocked-down breast cancer cells, a common target gene of YTHDC2 in breast cancer cells was not identified. These findings suggest that while YTHDC2 is involved in malignant progression of breast cancers, the mechanism by which YTHDC2 regulates those phenotypes is different between subtypes of breast cancers.

DOI

オンラインPRO情報システムによる乳がん患者の精神状態と生活の質変化に関する研究

石貫 智裕, 九冨 五郎, 沖田 憲司, 島 宏彰, 和田 朝香, 青木 武士, 吉田 寛, 渡邉 学, 横尾 英樹, 問山 裕二, 大西 浩文, 大柳 俊夫, 水口 徹

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  60回   P63 - 5  2022.10

アベマシクリブの副作用と鑑別が困難であった乳癌小腸転移の1例

野田 愛, 待木 隆志, 植木 知身, 向谷 充宏, 島 宏彰, 九冨 五郎, 竹政 伊知朗

北海道外科雑誌 ( 北海道外科学会 )  66 ( 2 ) 145 - 145  2021.12

HER2陽性乳癌における周術期抗HER2療法の心毒性の検討

和田 朝香, 九冨 五郎, 島 宏彰, 里見 蕗乃, 空閑 陽子, 佐藤 公則, 竹政 伊知朗, 大和田 渉

北海道外科雑誌 ( 北海道外科学会 )  66 ( 2 ) 155 - 155  2021.12

An Optimal Timing for Removing a Drain After Breast Surgery: A Systematic Review and Meta-Analysis.

Hiroaki Shima, Goro Kutomi, Kiminori Sato, Yoko Kuga, Asaka Wada, Fukino Satomi, Satoko Uno, Noriko Nisikawa, Hidekazu Kameshima, Tosei Ohmura, Toru Mizuguchi, Ichiro Takemasa

The Journal of surgical research   267   267 - 273  2021.11  [International journal]

　View Summary

BACKGROUND: In clinical practice, drains had been routinely used for reducing seroma formation after breast surgery. However, an optimal timing to remove drains does not identify yet. METHODS: This study aimed to compare the clinical outcome, such as seroma formation, surgical site infection (SSI), and a length of hospital stay between early removal and late removal. A systematic review was performed using PubMed, MEDLINE, and the Cochrane Library. Breast cancer patients who received surgery using drains were eligible. Those parameters were compared between early vs late removal. RESULTS: Eleven studies included in this meta-analysis. Seroma formation in the early removal group was significantly higher than the one in the late removal group (RR = 1.58: 95%CI [1.25-2.01], P = 0.0001), meanwhile no significant difference was found among the groups for SSI (RR = 0.82: 95%CI [0.51-1.31], P= 0.40). A length of hospital stay in the early removal group was also significantly shorter than late removal (RR -3.31: 95%CI [-5.13-1.49], P = 0.0004). CONCLUSIONS: Seroma formation was significantly higher in patients who had early drain removal. Conversely, SSI incidence was low, and early removal did not increase SSI incidence. In conclusion, early drain removal has no proved clinical benefit in these settings besides reduction of hospital stays.

DOI PubMed

転移再発乳がんに対するエリブリン及び次治療の有効性

和田 朝香, 九冨 五郎, 島 宏彰, 里見 蕗乃, 空閑 陽子, 及能 大輔, 竹政 伊知朗

日本癌治療学会学術集会抄録集 ( (一社)日本癌治療学会 )  59回   P2 - 2  2021.10

Comparing the extent of breast cancer tumors through contrast-enhanced ultrasound vs B-mode, opposed with pathology: evergreen study.

Hiroaki Shima, Toshitaka Okuno, Takashi Nakamura, Aya Noro, Midori Noma, Megumi Sato, Terumi Kaga, Yukio Mituzuka, Keitaro Kamei, Yumi Imayoshi, Toshikazu Ito, Shinsaku Kanazawa, Kumiko Kato, Goro Kutomi, Ryuzo Sekiguchi, Mitsuru Mori, Hasegawa Tadashi, Toshiko Hirai, Ichiro Takemasa

Breast cancer (Tokyo, Japan)   28 ( 2 ) 405 - 413  2021.03  [Domestic journal]

　View Summary

BACKGROUND: To prove the efficacy of contrast-enhanced ultrasound (CEUS) in determining the extent of resection, more evidence about B-mode and CEUS as opposed to pathology is required. We compared maximum tumor width measured on B-mode/CEUS images with that determined pathologically. METHODS: In this retrospective multicenter study, 152 operable breast cancer patients who had undergone both B-mode and CEUS were analyzed. Maximum tumor width on B-mode and CEUS, and on the postoperative pathological examination (P), was measured by the participating investigators. In addition, maximum width was assessed in B-mode and CEUS image sets by independent reviewers blinded to all patient information. We analyzed differences in maximum width between CEUS, B-mode and P. RESULTS: The mean widths as measured by the participating investigators were 15 ± 7 mm (B-mode), 19 ± 8 mm (CEUS), and 17 ± 9 mm (P). The difference subtracted P from B-mode was - 3 ± 7 mm (p < 0.0001), and that from CEUS was 1 ± 6 mm (p = 0.0163). The mean widths as measured by the independent reviewers were 16 ± 7 mm (B-mode) and 18 ± 7 mm (CEUS). The difference subtracted P from B-mode was - 2 ± 8 mm (p = 0.0114), while that from CEUS was 1 ± 7 mm (p = 0.1921). CONCLUSIONS: Maximum lesion width measurement showed a tendency to increase in the order of B-mode, to P and CEUS. The difference in measurement between P and B-mode was significant, but there was no significant between CEUS and P. These results provide additional information of tendency patterns in measuring the maximum lesion width through enhancement on CEUS.

DOI PubMed

Erector spinae plane block versus retrolaminar block for postoperative analgesia after breast surgery: a randomized controlled trial.

Sayaka Sotome, Atsushi Sawada, Asaka Wada, Hiroaki Shima, Goro Kutomi, Michiaki Yamakage

Journal of anesthesia   35 ( 1 ) 27 - 34  2021.02  [Domestic journal]

　View Summary

PURPOSE: The newly introduced erector spinae plane block (ESPB) has given anesthesiologists an alternative regional anesthetic technique for thoracic analgesia. Although ESPB and retrolaminar block (RLB) have similar puncture sites, no clinical study comparing ESPB and RLB has been reported. The aim of this study was to compare ESPB and RLB in terms of analgesic efficacy in the context of multimodal analgesia following breast surgery. METHODS: Fifty female patients undergoing breast surgery under general anesthesia were randomly allocated to receive either ultrasound-guided ESPB or RLB with 20 mL of 0.375% levobupivacaine for postoperative analgesia. The primary outcome was analgesic efficacy in terms of time to first postoperative rescue analgesic after the block procedure. The secondary outcomes were consumption of remifentanil during anesthesia, pain intensity at rest for 24 h postoperatively, and occurrence of postoperative nausea and vomiting (PONV). RESULTS: After excluding five patients, 45 patients (22 and 23 patients in the ESPB and RLB group, respectively) were analyzed. Median time until the first postoperative rescue analgesic after the block procedure in the ESPB group was not significantly longer than that in the RLB group (8.6 [range 2.7-24] vs. 4.8 [3.0-24] h; P = 0.83). There was no significant difference in the consumption of remifentanil during anesthesia, pain intensity at rest for 24 h postoperatively, and occurrence of PONV between the two groups. CONCLUSION: ESPB is equivalent, and not superior, to RLB for postoperative analgesia after breast surgery when 20 mL of 0.375% levobupivacaine is injected at the fourth thoracic vertebra.

DOI PubMed

Surgical advantage of ultrasonically activated devices during axillary lymph node dissection for breast cancer

Goro Kutomi, Hiroaki Shima, Hideki Maeda, Fukino Satomi, Asaka Wada, Kiminori Sato, Toru Mizuguchi, Ichiro Takemasa

International Surgery ( International College of Surgeons )  105 ( 1-3 ) 623 - 627  2021

　View Summary

Purposes: Axillary dissection is the gold standard for axillary lymph node metastasis in breast cancer patients. We compared surgical outcomes between ultrasonically activated devices (USADs) and thermal scalpel (TS) during axillary lymph node dissection in breast cancer patients. Methods:We conducted a retrospective analysis for 73 patients using TS between June 2012 to May 2016 and 63 patients using USADs between June 2016 to January 2019 in the breast cancer patients who received axillary dissection. Surgical outcomes were compared among the groups statistically. Results: Median operative time in the USAD group was significantly shorter than in the TS group (136 versus 182 minutes, P , 0.001). Intraoperative blood loss in the USAD group was also significantly lower than in the TS group (35 versus 120 mL, P , 0.001). Furthermore, the total drainage discharge in the USAD group was also significantly lower than in the TS group (570 versus 700 mL, P 0.016). The lymphedema frequency in the USAD group was significantly less than in the TS groups (1 of 63 versus 7 of 73, P 0.0296). Conclusion: The USADs could improve surgical outcomes, such as lymphedema, for axillary dissection of the breast cancer surgery compared with TS.

DOI